Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) doses its first patient suffering from lung carcinoma as part of its INSIGHT-003 study
- The patient was treated with the company’s lead product, efti, in combination with an existing approved standard of care treatment
- The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022
- Immutep is trading up two per cent at 51 cents at 11:57 am AEST
Immutep (IMM) has dosed its first patient suffering from lung carcinoma as part of its INSIGHT-003 study.
INSIGHT-003 is a trial conducted by the Institute of Clinical Cancer Research IKF in Frankfurt. The trial will involve patients receiving 30 milligrams of subcutaneous doses of eftilagimod alpha (efti) every two weeks.
The biotechnology company enrolled and dosed the patient – who suffers from metastatic non-small cell lung carcinoma – with pembrolizumab plus doublet chemotherapy combined with Immutep’s lead product candidate, efti.
The study looks to evaluate a triple combination therapy consisting of efti in conjunction with an existing approved standard of care to assess the treatment’s safety, tolerability and initial efficacy of the combination.
“INSIGHT-003 is the first time a triple combination therapy consisting of efti plus anti-PD-1 plus chemo is administered,” Immutep Chief Strategy Officer and Chief Medical officer Frédéric Triebel said.
“We are evaluating how efti might boost an approved chemotherapy and anti-PD-1 combination therapy, looking at safety and initial activity,” Dr Triebel said.
The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022.
Immutep was trading up two per cent at 51 cents at 11:57 am AEST.
